Five-Year Results of a Prospective Multicenter Trial: AdVance™ XP for Postprostatectomy Incontinence in Patients with Favorable Prognostic Factors

Mumm JN et al. *Urol Int.* 2021;105(5-6):421-7.

Objective of the study

Assess the security, value and efficacy of the second-generation AdVance XP Male Sling.

Patient Selection*

Patients excluded from the AdVance XP Sling study (who may be candidates for the AMS 800™ Artificial Urinary Sphincter):

- Earlier incontinence surgery
- Nocturnal urinary incontinence
- Former radiotherapy
- Functional urethra < 1cm during re-positioning test
- Poor external sphincter contractility
- More than 8 pads per day
- Previous history of urge incontinence

* These are the exclusion criteria for this study, these are not the exclusion criteria for the device itself.

115 consecutive patients included

Follow-up at 3, 6, 12, 24, 36, 48 and 60 months.

Definitions

- **Cure:** 0 pads in 24h or a maximum of 5g in the 24-h pad test.
- **Improvement:** ≥50% reduction in the 24-h pad test.
- **Failures:** < 50% reduction in the 24-h pad test.

Study results on next page

Long-term Efficacy



Complications

Intraoperative complications: none

Infections: none

Erosions: none

Pain: "no participant was in need of pain relief therapy in the prolonged post-op phase for over 4 weeks"

De-novo urge incontinence
(Clavien -Dindo IIa): 4.3%

Urinary Tract Infection
(Clavien-Dindo IIb): 0.9%

Single sling arm dissection
(Clavien-Dindo IIIb): 7.8%

3 patients received post AdVance XP Sling irradiation. For 2 of these, incontinence symptoms returned.

	Mean 24-hr pad test (grams)	ICIQ, mean	IQOL
Baseline (N=115)	272.0	14.9	67.3
24 months (N=114)	19.0	4.8	97.0
48 months (N=85)	33.8	5.3	96.9
60 months (N=59*)	18.3	5.0	96.8

* N=59 (24 patients lost to follow-up, 2 patients deceased, 30 patients have not reached 60-month endpoint/other)

Conclusion

"The AdVance XP displays excellent continence results and secure effectiveness over a 5-year period. Moreover, these data are demonstrating low complication rates and improved quality of life in the long-term use of AdVance XP."

Earlier articles on this study

Bauer RM, Grabbert MT, Klehr B, et al. **36-month** data for the AdVance XP male sling: results of a prospective multicentre study. *BJU Int*. 2017 Apr;119(4):626-30.

Bauer RM, Gozzi C, Klehr B, et al. AdVance XP male sling: **2-year** results of a multicenter study. *World J Urol*. 2016 Jul;34(7):1025-30.

Grabbert M, Mumm JN, Klehr B, et al. Extended follow-up of the AdVance XP male sling in the treatment of male urinary stress incontinence after **48 months**: Results of a prospective and multicenter study. *Neurourol Urodyn*. 2019 Sep;38(7):1973-8.

Link to full article: Five-Year Results of a Prospective Multicenter Trial: AdVance XP for Postprostatectomy-Incontinence in Patients with Favorable Prognostic Factors (karger.com)

Boston Scientific
Advancing science for life™

Boston Scientific Corporation
300 Boston Scientific Way
Marlborough, MA 01752
www.bostonscientific.com

MH-1025504-AA JUN 2021